Cargando…

Small-Molecule PROTACs for Cancer Immunotherapy

Unsatisfactory physicochemical properties of macromolecular drugs seriously hinder their application in tumor immunotherapy. However, these problems can be effectively solved by small-molecule compounds. In the promising field of small-molecule drug development, proteolysis targeting chimera (PROTAC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Zefan, Zhang, Yajun, Xiang, Yucheng, Kang, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458232/ https://www.ncbi.nlm.nih.gov/pubmed/36080223 http://dx.doi.org/10.3390/molecules27175439

Ejemplares similares

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
por: Ma, Sinan, et al.
Publicado: (2022)

Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
por: An, Sainan, et al.
Publicado: (2018)

Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
por: Fang, Yuan, et al.
Publicado: (2020)

Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs
por: Naito, Mikihiko, et al.
Publicado: (2019)

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
por: Moon, Yujeong, et al.
Publicado: (2023)

PROTACs in gastrointestinal cancers
por: Chen, Yu, et al.
Publicado: (2022)

Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer
por: Jin, Jinmei, et al.
Publicado: (2022)

Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery
por: Pei, Haixiang, et al.
Publicado: (2019)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
por: Negi, Arvind, et al.
Publicado: (2022)

Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology
por: Liu, Zefan, et al.
Publicado: (2022)

In-situ formed thermosensitive hydrogel amplifies statin-mediated immune checkpoint blockade for coordinated tumor chemo-immunotherapy
por: Liu, Zefan, et al.
Publicado: (2023)

PROTACs in the Management of Prostate Cancer
por: Yedla, Poornachandra, et al.
Publicado: (2023)

PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020)

Clinical considerations for the design of PROTACs in cancer
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2022)

Targeting Oncoproteins for Degradation by Small Molecule-Based Proteolysis-Targeting Chimeras (PROTACs) in Sex Hormone-Dependent Cancers
por: Liu, Li, et al.
Publicado: (2022)

PROTACs: A novel strategy for cancer drug discovery and development
por: Han, Xin, et al.
Publicado: (2023)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
por: Li, Xinyi, et al.
Publicado: (2022)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

First small-molecule PROTACs for G protein-coupled receptors: inducing α(1A)-adrenergic receptor degradation
por: Li, Zhenzhen, et al.
Publicado: (2020)

Degradation of proteins by PROTACs and other strategies
por: Wang, Yang, et al.
Publicado: (2020)

PROTAC-DB 2.0: an updated database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2022)

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
por: Li, Xin, et al.
Publicado: (2020)

A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models
por: Wang, Weijin, et al.
Publicado: (2021)

PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities
por: Liu, Xuelian, et al.
Publicado: (2023)

The PROTAC technology in drug development
por: Zou, Yutian, et al.
Publicado: (2019)

Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs
por: Ishikawa, Minoru, et al.
Publicado: (2020)

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
por: Li, Rui, et al.
Publicado: (2022)

Small-Molecule Targets in Tumor Immunotherapy
por: Zhu, Hui-Fang, et al.
Publicado: (2018)

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
por: Li, Fenglei, et al.
Publicado: (2022)

Antiviral PROTACs: Opportunity borne with challenge
por: Liang, Jinsen, et al.
Publicado: (2023)

Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation
por: Maniaci, Chiara, et al.
Publicado: (2017)

Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer
por: Adderley, H., et al.
Publicado: (2020)

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
por: Kelm, Jeremy M., et al.
Publicado: (2023)

PROTACs: great opportunities for academia and industry
por: Sun, Xiuyun, et al.
Publicado: (2019)

An overview of PROTACs: a promising drug discovery paradigm
por: Liu, Zi, et al.
Publicado: (2022)

PROTAC: targeted drug strategy. Principles and limitations
por: Koroleva, O. A., et al.
Publicado: (2022)

Novel approaches for the rational design of PROTAC linkers
por: Zagidullin, Almaz, et al.
Publicado: (2020)

Recent Advances in PROTAC-Based Antiviral Strategies
por: Ahmad, Haleema, et al.
Publicado: (2023)

Recent Advances of Degradation Technologies Based on PROTAC Mechanism
por: Xiao, Mingchao, et al.
Publicado: (2022)

The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination
por: Jin, Jinmei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gtqstseqtsh5ffbe8mfb5jta2m